Literature DB >> 10588573

Neuronal loss and beta-amyloid removal in the amygdala of people with Down syndrome.

J Weģiel1, H M Wísniewski, J Moryś, M Tarnawski, I Kuchna, J Dziewiatkowski, T Pirttilä, T Krivimäki, T Lehtimäki, B Lach.   

Abstract

The decrease in the number of neurons free of neurofibrillary changes, neurons with neurofibrillary degeneration, and the total volume of beta-amyloid (A beta) deposits in the amygdala of people with Down syndrome and in late stages of Alzheimer disease were estimated by using morphometry and regression analysis. This model predicts that the duration of neurofibrillary changes from the pretangle stage to ghost tangles is approximately 4.7 years. The correlation between the decrease in the number of neurons and the decrease in the amount of A beta indicates that amyloid deposition is associated with neurons and that loss of neurons causes decrease in A beta deposition. The presence of neurons only with neurofibrillary tangles, and the absence of the amyloid deposits predicted by regression analysis suggest that neurons with tangles are not engaged in amyloid deposition. The disappearance of amyloid by approximately 2.2 years after loss of neurons free of neurofibrillary changes indicates that A beta deposits are degradable and removable and that even in severely atrophic amygdala, there are mechanisms of amyloid resolution. This study shows that in normal aging in the amygdala, extracellular A beta appears later than neurofibrillary changes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588573     DOI: 10.1016/s0197-4580(99)00060-3

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  4 in total

1.  Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease.

Authors:  Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Shuang Yong Ma; Jarek Wegiel; Eulalia Badmaev; Mony de Leon; Thomas Wisniewski; Barry Reisberg
Journal:  J Neuropathol Exp Neurol       Date:  2021-01-01       Impact factor: 3.685

2.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

3.  Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.

Authors:  Fabio M Simoes de Souza; Nicolas Busquet; Megan Blatner; Kenneth N Maclean; Diego Restrepo
Journal:  Sci Rep       Date:  2011-11-02       Impact factor: 4.379

4.  Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration.

Authors:  Jerzy Wegiel; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur-Kolecka; Humi Imaki; Jarek Wegiel; Pankaj D Mehta; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Tuula Pirttilla; Harry Frey; Terho Lehtimäki; Tarmo Kivimäki; Frank E Visser; Wouter Kamphorst; Anna Potempska; David Bolton; Julia R Currie; David L Miller
Journal:  Acta Neuropathol       Date:  2007-01-20       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.